News
Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics PURPOSE: The prognosis of metastatic/high-risk localized small round-cell tumors (SRCTs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback